vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and SunOpta Inc. (STKL). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $205.4M, roughly 1.4× SunOpta Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 0.4%, a 95.9% gap on every dollar of revenue. On growth, SunOpta Inc. posted the faster year-over-year revenue change (16.6% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 7.4%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
SunOpta, Inc. is a multi-national food and mineral company headquartered in Eden Prairie, Minnesota and founded in 1973 in Canada.
ACAD vs STKL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $205.4M |
| Net Profit | $273.6M | $816.0K |
| Gross Margin | 90.8% | 12.4% |
| Operating Margin | 6.1% | 3.3% |
| Net Margin | 96.3% | 0.4% |
| Revenue YoY | 9.4% | 16.6% |
| Net Profit YoY | 90.3% | 113.1% |
| EPS (diluted) | $1.61 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | — | ||
| Q3 25 | $278.6M | $205.4M | ||
| Q2 25 | $264.6M | $191.5M | ||
| Q1 25 | $244.3M | $201.6M | ||
| Q4 24 | $259.6M | $193.9M | ||
| Q3 24 | $250.4M | $175.9M | ||
| Q2 24 | $242.0M | $169.5M | ||
| Q1 24 | $205.8M | $184.4M |
| Q4 25 | $273.6M | — | ||
| Q3 25 | $71.8M | $816.0K | ||
| Q2 25 | $26.7M | $4.4M | ||
| Q1 25 | $19.0M | $4.8M | ||
| Q4 24 | $143.7M | $-8.7M | ||
| Q3 24 | $32.8M | $-6.2M | ||
| Q2 24 | $33.4M | $-5.3M | ||
| Q1 24 | $16.6M | $2.9M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | 12.4% | ||
| Q2 25 | 92.2% | 14.8% | ||
| Q1 25 | 91.7% | 15.0% | ||
| Q4 24 | 91.6% | 10.9% | ||
| Q3 24 | 92.5% | 13.0% | ||
| Q2 24 | 92.5% | 12.5% | ||
| Q1 24 | 88.8% | 16.8% |
| Q4 25 | 6.1% | — | ||
| Q3 25 | 12.8% | 3.3% | ||
| Q2 25 | 12.2% | 5.5% | ||
| Q1 25 | 7.9% | 5.2% | ||
| Q4 24 | 59.1% | 1.4% | ||
| Q3 24 | 12.6% | 0.5% | ||
| Q2 24 | 12.6% | 1.2% | ||
| Q1 24 | 7.4% | 5.5% |
| Q4 25 | 96.3% | — | ||
| Q3 25 | 25.8% | 0.4% | ||
| Q2 25 | 10.1% | 2.3% | ||
| Q1 25 | 7.8% | 2.4% | ||
| Q4 24 | 55.4% | -4.5% | ||
| Q3 24 | 13.1% | -3.5% | ||
| Q2 24 | 13.8% | -3.1% | ||
| Q1 24 | 8.0% | 1.6% |
| Q4 25 | $1.61 | — | ||
| Q3 25 | $0.42 | $0.01 | ||
| Q2 25 | $0.16 | $0.03 | ||
| Q1 25 | $0.11 | $0.04 | ||
| Q4 24 | $0.86 | $-0.08 | ||
| Q3 24 | $0.20 | $-0.05 | ||
| Q2 24 | $0.20 | $-0.04 | ||
| Q1 24 | $0.10 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $2.2M |
| Total DebtLower is stronger | — | $250.8M |
| Stockholders' EquityBook value | $1.2B | $162.8M |
| Total Assets | $1.6B | $694.1M |
| Debt / EquityLower = less leverage | — | 1.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | $2.2M | ||
| Q2 25 | $253.6M | $2.2M | ||
| Q1 25 | $217.7M | $2.3M | ||
| Q4 24 | $319.6M | $1.6M | ||
| Q3 24 | $155.1M | $2.9M | ||
| Q2 24 | $177.1M | $3.2M | ||
| Q1 24 | $204.7M | $1.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $250.8M | ||
| Q2 25 | — | $263.3M | ||
| Q1 25 | — | $260.6M | ||
| Q4 24 | — | $265.2M | ||
| Q3 24 | — | $289.9M | ||
| Q2 24 | — | $303.1M | ||
| Q1 24 | — | $258.8M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $917.3M | $162.8M | ||
| Q2 25 | $822.4M | $159.8M | ||
| Q1 25 | $765.2M | $154.8M | ||
| Q4 24 | $732.8M | $148.6M | ||
| Q3 24 | $577.2M | $155.0M | ||
| Q2 24 | $516.7M | $158.8M | ||
| Q1 24 | $464.0M | $163.6M |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.3B | $694.1M | ||
| Q2 25 | $1.2B | $704.9M | ||
| Q1 25 | $1.1B | $690.7M | ||
| Q4 24 | $1.2B | $668.5M | ||
| Q3 24 | $976.9M | $699.3M | ||
| Q2 24 | $914.1M | $704.7M | ||
| Q1 24 | $855.1M | $671.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.54× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.68× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | 1.91× | ||
| Q1 24 | — | 1.58× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $16.3M |
| Free Cash FlowOCF − Capex | — | $12.1M |
| FCF MarginFCF / Revenue | — | 5.9% |
| Capex IntensityCapex / Revenue | — | 2.1% |
| Cash ConversionOCF / Net Profit | -0.18× | 20.03× |
| TTM Free Cash FlowTrailing 4 quarters | — | $36.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | — | ||
| Q3 25 | $74.3M | $16.3M | ||
| Q2 25 | $64.0M | $-4.5M | ||
| Q1 25 | $20.3M | $22.3M | ||
| Q4 24 | $40.4M | $33.1M | ||
| Q3 24 | $63.2M | $17.2M | ||
| Q2 24 | $25.0M | $-5.6M | ||
| Q1 24 | $29.1M | $5.3M |
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | $12.1M | ||
| Q2 25 | — | $-9.2M | ||
| Q1 25 | — | $9.5M | ||
| Q4 24 | — | $24.0M | ||
| Q3 24 | $63.2M | $11.7M | ||
| Q2 24 | — | $-15.3M | ||
| Q1 24 | — | $-2.3M |
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | 5.9% | ||
| Q2 25 | — | -4.8% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | 12.4% | ||
| Q3 24 | 25.2% | 6.6% | ||
| Q2 24 | — | -9.0% | ||
| Q1 24 | — | -1.2% |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | 2.1% | ||
| Q2 25 | — | 2.5% | ||
| Q1 25 | — | 6.3% | ||
| Q4 24 | — | 4.7% | ||
| Q3 24 | 0.0% | 3.2% | ||
| Q2 24 | — | 5.7% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | 20.03× | ||
| Q2 25 | 2.40× | -1.03× | ||
| Q1 25 | 1.07× | 4.63× | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | 1.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
STKL
| Beverages And Broths | $161.4M | 79% |
| Fruit Snacks | $40.9M | 20% |
| Ingredients | $3.1M | 2% |
